Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 17135890 | USE OF ZC3H12B GENE OR PROTEIN AND METHOD FOR ESTABLISHING ANIMAL MODEL OF LIVER DISEASE | December 2020 | January 2025 | Allow | 48 | 1 | 1 | No | No |
| 15734605 | THERAPEUTIC DOSAGE REGIMENS COMPRISING ADHERENT STROMAL CELLS | December 2020 | June 2024 | Abandon | 42 | 1 | 0 | No | No |
| 17102269 | METHODS FOR PREPARING PLATELET PRODUCTS | November 2020 | October 2023 | Abandon | 34 | 1 | 0 | No | No |
| 17096138 | PRODUCTION OF ENGINEERED T-CELLS BY SLEEPING BEAUTY TRANSPOSON COUPLED WITH METHOTREXATE SELECTION | November 2020 | November 2024 | Allow | 48 | 2 | 0 | Yes | No |
| 16967074 | NOVEL RECOMBINANT PLASMA MEMBRANE-BASED VESICLE, FOR TREATING CANCER | August 2020 | March 2025 | Allow | 56 | 2 | 1 | No | No |
| 16966204 | METHODS OF TREATING OPTIC NERVE DISEASES USING NEURAL PROGENITOR CELL GROWTH FACTORS | July 2020 | October 2024 | Allow | 51 | 2 | 2 | Yes | No |
| 16927924 | SYSTEM AND METHODS RELATING TO CHIMERIC AUTOANTIBODY RECEPTORS | July 2020 | June 2025 | Allow | 59 | 2 | 1 | Yes | No |
| 16651200 | FACTOR VIII OR FACTOR IX GENE KNOCKOUT RABBIT, METHOD FOR PREPARING SAME AND USE THEREOF | July 2020 | April 2024 | Abandon | 49 | 0 | 1 | No | No |
| 16961130 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING MUSCULAR DISEASE OR CACHEXIA COMPRISING, AS ACTIVE INGREDIENT, miRNA LOCATED IN DLK1-DIO3 CLUSTER OR VARIANT THEREOF | July 2020 | March 2024 | Abandon | 44 | 2 | 0 | No | No |
| 16960370 | BIDIRECTIONAL CHEF1 VECTORS | July 2020 | June 2025 | Abandon | 60 | 3 | 0 | No | No |
| 16649417 | METHOD FOR PRODUCING NATURAL KILLER CELL AND USE THEREOF | July 2020 | May 2025 | Allow | 60 | 5 | 0 | Yes | No |
| 16907748 | LIPIN-1 AS A NOVEL THERAPY TARGET OF MUSCULAR DYSTROPHY | June 2020 | May 2024 | Allow | 46 | 3 | 1 | Yes | No |
| 16955647 | NOVEL MULTI-ORGAN-CHIPS ESTABLISHING DIFFERENTIATION OF IPSC-DERIVED CELLS INTO ORGAN EQUIVALENTS | June 2020 | June 2024 | Abandon | 48 | 2 | 1 | No | No |
| 15929408 | TARGETING PEPTIDE TO DELIVER A COMPOUND TO OOCYTES | April 2020 | April 2025 | Allow | 60 | 2 | 1 | Yes | No |
| 16760902 | ENGINEERED NUCLEASES THAT TARGET HUMAN AND CANINE FACTOR VIII GENES AS A TREATMENT FOR HEMOPHILIA A | April 2020 | February 2024 | Abandon | 46 | 1 | 1 | No | No |
| 16760630 | MEDICINE FOR TISSUE REGENERATION, AND PREPARATION METHOD THEREFOR | April 2020 | October 2024 | Abandon | 54 | 4 | 0 | Yes | No |
| 16759263 | METHODS AND COMPOSITIONS FOR TREATING CD33+ CANCERS AND IMPROVING IN VIVO PERSISTENCE OF CHIMERIC ANTIGEN RECEPTOR T CELLS | April 2020 | March 2024 | Allow | 47 | 2 | 1 | Yes | No |
| 16757198 | METHODS AND COMPOUNDS FOR IMPROVED IMMUNE CELL THERAPY | April 2020 | February 2024 | Allow | 46 | 2 | 1 | No | No |
| 16755862 | ENHANCED REPROGRAMMING OF SOMATIC CELLS | April 2020 | August 2023 | Abandon | 40 | 0 | 1 | No | No |
| 16839031 | System and Method for the Production, Formulation and Use of Conditioned Media, Cultured Cells and the Factors Included Therein | April 2020 | June 2025 | Allow | 60 | 4 | 1 | No | No |
| 16649084 | CELLULAR REPROGRAMMING USING TEMPORAL AND TRANSIENT PLASMID VECTOR EXPRESSION SYSTEM | March 2020 | November 2024 | Allow | 56 | 3 | 1 | Yes | No |
| 16793600 | In Vitro Fertilization Media with Antiviral Medicine | February 2020 | October 2023 | Abandon | 43 | 1 | 0 | No | No |
| 16636153 | GENERATION OF OLIGODENDROGENIC NEURAL PROGENITOR CELLS | February 2020 | August 2023 | Allow | 42 | 1 | 1 | No | No |
| 16632741 | A VIRUS FOR TREATMENT OF TUMOR | January 2020 | June 2023 | Allow | 41 | 1 | 1 | Yes | No |
| 16629169 | MODULATING BIOMARKERS TO INCREASE TUMOR IMMUNITY AND IMPROVE THE EFFICACY OF CANCER IMMUNOTHERAPY | January 2020 | June 2025 | Abandon | 60 | 2 | 2 | No | No |
| 16727647 | DIET CONTROLLED EXPRESSION OF A NUCLEIC ACID ENCODING A PRO-APOPTOTIC PROTEIN | December 2019 | May 2025 | Allow | 60 | 5 | 0 | No | No |
| 16711409 | METHODS AND COMPOSITIONS FOR EFFICIENT AND PRECISE GENE EDITING IN MAMMALIAN BRAIN TO PREVENT OR TREAT NERVOUS SYSTEM DISORDERS | December 2019 | March 2024 | Abandon | 51 | 1 | 0 | No | No |
| 16619570 | T-CELLS MODIFIED TO OVEREXPRESS PHF19 | December 2019 | August 2023 | Allow | 45 | 1 | 1 | Yes | No |
| 16604596 | RESPIRATORY AND SWEAT GLAND IONOCYTES | October 2019 | October 2024 | Allow | 60 | 3 | 1 | Yes | No |
| 16517342 | Selection and Cloning of T Lymphocytes in a Microfluidic Device | July 2019 | November 2023 | Abandon | 52 | 2 | 1 | No | No |
| 16476323 | THREE-DIMENSIONAL TUMOR MODELS, METHODS OF MANUFACTURING SAME AND USES THEREOF | July 2019 | June 2025 | Allow | 60 | 4 | 1 | Yes | No |
| 16470951 | PEPTIDE FOR TREATING AGE-RELATED MACULAR DEGENERATION | June 2019 | May 2024 | Abandon | 59 | 2 | 2 | No | No |
| 16320075 | IMMUNOMODULATORY POLYPEPTIDES AND RELATED COMPOSITIONS AND METHODS | January 2019 | January 2025 | Allow | 60 | 5 | 1 | No | Yes |
| 15623828 | TARGETED CARRIERS FOR INTRACELLULAR DRUG DELIVERY | June 2017 | November 2023 | Abandon | 60 | 7 | 1 | Yes | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner ABUZEINEH, HANAN ISAM.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 0.0% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner ABUZEINEH, HANAN ISAM works in Art Unit 1633 and has examined 34 patent applications in our dataset. With an allowance rate of 55.9%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 51 months.
Examiner ABUZEINEH, HANAN ISAM's allowance rate of 55.9% places them in the 18% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by ABUZEINEH, HANAN ISAM receive 2.32 office actions before reaching final disposition. This places the examiner in the 62% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.
The median time to disposition (half-life) for applications examined by ABUZEINEH, HANAN ISAM is 51 months. This places the examiner in the 6% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a +50.7% benefit to allowance rate for applications examined by ABUZEINEH, HANAN ISAM. This interview benefit is in the 93% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 28.6% of applications are subsequently allowed. This success rate is in the 55% percentile among all examiners. Strategic Insight: RCEs show above-average effectiveness with this examiner. Consider whether your amendments or new arguments are strong enough to warrant an RCE versus filing a continuation.
This examiner enters after-final amendments leading to allowance in 18.8% of cases where such amendments are filed. This entry rate is in the 24% percentile among all examiners. Strategic Recommendation: This examiner rarely enters after-final amendments compared to other examiners. You should generally plan to file an RCE or appeal rather than relying on after-final amendment entry. Per MPEP § 714.12, primary examiners have discretion in entering after-final amendments, and this examiner exercises that discretion conservatively.
When applicants request a pre-appeal conference (PAC) with this examiner, 200.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 93% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences are highly effective with this examiner compared to others. Before filing a full appeal brief, strongly consider requesting a PAC. The PAC provides an opportunity for the examiner and supervisory personnel to reconsider the rejection before the case proceeds to the PTAB.
This examiner withdraws rejections or reopens prosecution in 100.0% of appeals filed. This is in the 86% percentile among all examiners. Of these withdrawals, 100.0% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.
When applicants file petitions regarding this examiner's actions, 100.0% are granted (fully or in part). This grant rate is in the 90% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 1% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 10.5% of allowed cases (in the 90% percentile). Per MPEP § 714.14, a Quayle action indicates that all claims are allowable but formal matters remain. This examiner frequently uses Quayle actions compared to other examiners, which is a positive indicator that once substantive issues are resolved, allowance follows quickly.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.